Radiotherapy during COVID-19

• Date :
• 1    
  0

COVID-19 in Italy: managing breast cancer patients

• Date :
• 1    
  0

The importance of surgical education in implementing novel AI techniques

• Date :
• 0    
  0

Chemo-immunotherapy for TNBC

• Date :
• 0    
  0

HER2-E pCR with anti-HER2-based neoadjuvant therapies

• Date :
• 0    
  0

HER2 blockade in HER2-E induces low-proliferative luminal A phenotype

• Date :
• 0    
  0

CORALLEEN: kicking chemo?

• Date :
• 0    
  0

EMBRACA & OlympiAD: targeting DNA repair

• Date :
• 0    
  0

CLEOPATRA & EMILIA: HER2+ mBC state-of-the-art

• Date :
• 0    
  0

Chemo-immunotherapy for TNBC

• Date :
• 0    
  0

SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC

• Date :
• 0    
  0

Cabo alone or with trast for BC with brain mets?

• Date :
• 0    
  0

TILS related to BRCA-like status

• Date :
• 0    
  0

ROXANE: impact of 21-gene assay on treatment for early breast cancer

• Date :
• 0    
  0

Real-world: efficacy of everolimus + exemestane HR+, HER2- BC

• Date :
• 0    
  0

Future outlook for breast cancer surgery

• Date :
• 0    
  0

Characterizing the immune microenvironment before and following anti-HER2 neoadjuvant therapy

• Date :
• 0    
  0

mTNBC: tumor mutational burden & PTEN Alterations as molecular correlates

• Date :
• 0    
  0

Unmet needs in breast cancer

• Date :
• 0    
  0

Mismatch repair protein loss in breast cancer

• Date :
• 0    
  0

ShortHER study: validating the AJCC prognostic stage in HER2+ breast cancer

• Date :
• 0    
  0

Effects of BMI on PFS in the MONARCH 1 and MONARCH 2 trial

• Date :
• 0    
  0

Using genomic techniques to guide personalized medicine in breast cancer

• Date :
• 0    
  0

The local treatment of the axilla in early breast cancer

• Date :
• 0    
  0

Empowering communication in emergency care as a result of COVID-19

• Date :
• 0    
  0

Importance of biomarkers when evaluating heterogeneity in HER2+ metastatic BC

• Date :
• 0    
  0

The right biomarker for the right patient

• Date :
• 0    
  0

NSABP B-41: genes and signatures associated with pCR

• Date :
• 0    
  0

The multidisciplinary care of cancer

• Date :
• 0    
  0

Breast Cancer-related lymphedema

• Date :
• 0    
  0

Designing innovative clinical trials in BC

• Date :
• 0    
  0

Pembro plus palliative radio for HR+ mBC

• Date :
• 0    
  0

The importance of BMI as a prognostic factor in breast cancer

• Date :
• 0    
  0

Genetic testing: changing the face of cancer care

• Date :
• 0    
  0

Nationwide study by the BCR and BSMO on the effect of surgery on mBC patients

• Date :
• 0    
  0

Latest advances in breast cancer research

• Date :
• 0    
  0

Loss of HER2 after neoadjuvant treatment of HER2+ early BC

• Date :
• 0    
  0

PTEN expression as a complementary biomarker

• Date :
• 0    
  0

FAST FORWARD Phase III: Hypofractionated whole breast irradiation

• Date :
• 0    
  0

Beyond HER2: dissecting tumor heterogeneity

• Date :
• 0    
  0

HER2CLIMB: tucatinib in combination w/ capecitabine & trastuzumab

• Date :
• 0    
  0

Personalizing immunotherapy beyond PDL1 expression

• Date :
• 0    
  0

HR+ breast cancer: endocrine therapy, surgery and radiotherapy

• Date :
• 0    
  0

Value of radiomics and AI in cancer treatment

• Date :
• 0    
  0

The use of AI and augmented reality in breast cancer surgery

• Date :
• 0    
  0

Endocrine therapy in premenopausal women with HR+ breast cancer

• Date :
• 0    
  0

Latest news in breast cancer surgery

• Date :
• 0    
  0

The role of surgery in metastatic breast cancer

• Date :
• 0    
  0

COVID-19 related stress and burnout in hospital staff

• Date :
• 0    
  0

Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355

• Date :
• 0    
  0

GELATO: carboplatin and atezolizumab in advanced lobular BC

• Date :
• 0    
  0

The future of breast cancer treatment

• Date :
• 0    
  0

MONARCH: Chemo-free options for triple-positive metastatic breast cancer

• Date :
• 0    
  0

CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC

• Date :
• 0    
  0

The gut microbiome & triple negative breast cancer

• Date :
• 0    
  0

LILAC: comparing cardiac safety of ABP 980 with trastuzumab

• Date :
• 0    
  0

Decision-making process for patients involved in clinical trials

• Date :
• 0    
  0

COVID-19 experience in Switzerland

• Date :
• 0    
  0

Targeting low HER2 expression with antibody-drug conjugates

• Date :
• 0    
  0

Advances and considerations in the treatment and management of HR+, HER2-, advanced breast cancer

• Date :
• 0    
  0

The treatment of BC brain metastases

• Date :
• 0    
  0

Is cardiac damage still relevant? How can it be avoided?

• Date :
• 0    
  0

The Oncoplastic Breast Consortium

• Date :
• 0    
  0

Current standards for HER2+ early stage breast cancer

• Date :
• 0    
  0

The evolution of breast cancer surgery

• Date :
• 0    
  0

TAXIS: tailored axillary surgery in clinically node-positive breast cancer

• Date :
• 0    
  0

Remarkable data: trastuzumab deruxtecan for HER2+ BC

• Date :
• 0    
  0

Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY & more

• Date :
• 0    
  0

PHranceSCa: evaluating patient satisfaction with subcutaneous pertuzumab and trastuzumab treatment

• Date :
• 0    
  0

Radiomics in the prediction of immunophenotypes in male breast cancer

• Date :
• 0    
  0

The impact of coronavirus on patient-doctor interactions in Portugal

• Date :
• 0    
  0

Exploring the use of olaparib in advanced breast cancer

• Date :
• 0    
  0

Managing breast cancer during pregnancy

• Date :
• 0    
  0

44e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse

• Date :
• 4172    
  0

14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024

• Date :
• 3833    
  0

Post ASCO-ESMO 2024 Fédération Francophone de Cancérologie Digestive

• Date :
• 3152    
  0

45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024

• Date :
• 6921    
  0

Molecular Analysis for Precision Oncology Congress - MAP 2024

• Date :
• 2501    
  0